At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 16 enrolled
Drug / intervention
GSK2336805 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Double-Blind, Randomized, Placebo-Controlled Study to Assess Safety, Efficacy, and Pharmacokinetics (PK) of GSK2336805 in Combination With Peginterferon and Ribavirin in Treatment-naive Chronic Hepatitis C Subjects With Hepatitis C Virus Genotypes 1 or 4
In Brief
A Phase 2 clinical trial evaluating GSK2336805, Pegylated interferon alfa-2a, and 2 other interventions for Hepatitis C, Chronic. Completed, enrolled 16 participants across 10 sites in 2 countries.
Detailed Summary
GSK2336805 is a hepatitis C virus (HCV) NS5A inhibitor being developed for the treatment of chronic hepatitis C (CHC). This study will assess the safety, antiviral activity, and pharmacokinetics of GSK2336805 alone and in combination with peginterferon alfa 2a and ribavirin in subjects with chronic hepatitis C (CHC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C, Chronic
CountriesPuerto Rico, United States
CollaboratorsPPD Development, LP
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2011
First PostedSep 2011
Primary CompletionDec 2011
TodayJul 2026
First PostedSep 23, 2011
Enrollment StartJul 7, 2011
Primary CompletionDec 5, 2011
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 14.8 years ago
Interventions
GSK2336805drug
Active Investigational Drug
Pegylated interferon alfa-2adrug
Standard of Care drug
Ribavirindrug
Standard of Care drug
GSK2336805 Matching Placebodrug
Placebo of Investigational Drug